Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials

BACKGROUND: In recent years, a number of clinical trials for antibody drugs targeting programmed cell death protein 1 (PD1)/programmed cell death 1 ligand 1 (PD-L1) have been carried out on recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN) and reported promising prospects. To...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Peng, Wang, Yanwei, Zhang, Wendi, Liu, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850637/
https://www.ncbi.nlm.nih.gov/pubmed/33530227
http://dx.doi.org/10.1097/MD.0000000000024339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850637/
https://www.ncbi.nlm.nih.gov/pubmed/33530227
http://dx.doi.org/10.1097/MD.0000000000024339

Ejemplares similares